Xencor (NASDAQ:XNCR) Director Richard Ranieri Sells 81,252 Shares of Company Stock

Xencor, Inc. (NASDAQ:XNCR) Director Richard Ranieri sold 81,252 shares of Xencor stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $39.25, for a total transaction of $3,189,141.00. Following the completion of the sale, the director owned 18,514 shares in the company, valued at approximately $726,674.50. This trade represents a 81.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xencor Price Performance

Shares of Xencor stock opened at $38.13 on Friday. Xencor, Inc. has a 12-month low of $10.38 and a 12-month high of $40.60. The company’s fifty day simple moving average is $27.13 and its two-hundred day simple moving average is $17.98.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, topping the consensus estimate of ($0.33) by $0.83. The firm had revenue of $116.52 million during the quarter, compared to analysts’ expectations of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The company’s quarterly revenue was up 453.3% compared to the same quarter last year. During the same period last year, the company posted ($0.08) EPS. On average, equities analysts expect that Xencor, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Bessemer Group Inc. lifted its position in Xencor by 18.7% during the 3rd quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 282 shares during the period. GAMMA Investing LLC grew its holdings in Xencor by 15.5% in the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 572 shares during the period. Allworth Financial LP increased its stake in shares of Xencor by 23.2% during the second quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 646 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its stake in shares of Xencor by 31.0% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,804 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 1,373 shares in the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Xencor by 1.5% during the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after purchasing an additional 1,534 shares in the last quarter.

Analysts Set New Price Targets

XNCR has been the topic of several research reports. Wall Street Zen raised Xencor from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Truist Financial upped their target price on Xencor from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Raymond James Financial increased their target price on Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on Xencor in a research note on Thursday, November 5th. They issued an “overweight” rating and a $70.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $42.22.

About Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.